1 Min Read
NEW YORK, Nov 26 (Reuters) - BioLine RX Ltd : * U.S.-listed shares up 7.3 percent premarket after phase 2a trial results for
inflammatory bowel disease treatment
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.